Combined Mycophenolate Mofetil and Minimal Dose Calcineurin Inhibitor Therapy in Liver Transplant Patients: Clinical Results of a Prospective Randomized Study

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2567-2569

  Beckebaum, S ^a   Klein, C G ^a   Sotiropoulos, G C ^a   Saner, F H ^a   Gerken, G ^a   Paul, A ^a   Cicinnati, V R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HERPES LABIALIS; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; BLOOD PRESSURE; CALCINEURIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SURVIVAL RATE; SURVIVORS;

EID: 68949204224     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.152     Document Type: Article

References (7)

1. Jain A., Vekatramanan R., Eghtesad B., et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 80 (2005) 859
2. Kornberg A., Kupper B., Hommann M., et al. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol 5 (2005) 141
3. Cantarovich M., Tzimas G.N., Barkun J., et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 76 (2003) 98
4. Pageaux G.P., Rostaing L., Calmus Y., et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 12 (2006) 1755
5. Fairbanks K.D., and Thuluvath P.J. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 10 (2004) 1189
6. Orlando G., Baiocchi L., Cardillo A., et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 13 (2007) 46
7. Moreno Planas J.M., Cuervas-Mons M., Rubio G.E., et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 10 (2004) 1650